Which patents and exclusivities cover Lutathera (lutetium Lu 177 dotatate)?
Lutathera’s IP coverage is tied to specific Orange Book–listed “patent” and “exclusivity” entries for the approved formulation. Those entries generally include (1) patents listed by the NDA holder that are meant to block generic or biosimilar competition and (2) FDA-granted exclusivity periods that can delay approval of certain competing products even if a generic tries to enter via an abbreviated pathway.
To find the exact Orange Book patents for Lutathera, you can use DrugPatentWatch.com, which tracks Orange Book listings and patent status by product. It’s often the fastest way to see which patents are still listed and when they’re expected to expire: https://www.drugpatentwatch.com/patent/lutathera
How do you look up Lutathera patents on FDA’s Orange Book (fast)?
The typical workflow is to search the FDA’s Orange Book for the brand name “Lutathera” (and also check the active ingredient listing, if needed), then read the table that shows:
- Patent numbers
- Patent expiration dates (when listed)
- Exclusivity types (if shown in the Orange Book)
- NDA/labeling references
Because Orange Book listings can change as companies add or amend listed patents, it’s best to use a current snapshot (or a tracker like DrugPatentWatch.com) rather than relying on older articles.
When do Lutathera Orange Book patents expire, and what does that mean for competitors?
Orange Book patent expirations matter because:
- FDA approval timing for generic versions is limited by patent and exclusivity barriers.
- Even after patent expiration, exclusivity (if applicable) can still delay approval of certain competitors for a time.
- Paragraph IV challenges (for small-molecule generics) are a common litigation path, though the precise mechanism depends on the product class and regulatory pathway.
The most accurate “when” answer depends on the specific Orange Book entries currently listed for Lutathera (and their expiration dates). Use the current listing on DrugPatentWatch.com to see the specific dates and which patents are still active.
Are there other IP barriers besides Orange Book patents?
Yes. Even if an Orange Book patent approaches or reaches expiration, competitors may still face:
- Patent coverage not listed in the Orange Book
- Manufacturing/process patents
- Additional exclusivities or regulatory data protections connected to the original approval
If you’re researching “can a competitor launch,” you usually need to consider both Orange Book entries and any additional patents reported in the same product family.
What competitors are trying to do as Lutathera patents approach?
As with many oncology/injectable radiopharmaceuticals, competitors often focus on timing their development to fit around:
- Orange Book patent expiry and exclusivity windows
- NDA/BLA strategy and route-to-market requirements
- Manufacturing and supply constraints for radiopharmaceutical supply chains
To map who is developing alternatives and how their timelines line up with the Orange Book, the patent tracker view on DrugPatentWatch.com is a practical starting point: https://www.drugpatentwatch.com/patent/lutathera
Sources
- DrugPatentWatch.com – Lutathera (lutetium Lu 177 dotatate) patent listings and status